Home>Topics>>Aegerion Pharmaceuticals Is Still Significantly Overvalued
Aegerion Pharmaceuticals Is Still Significantly Overvalued
Healthcare Sector and Stocks Analysis from Seeking Alpha
Tue, 19 Aug 2014
By Kanak Kanti De : Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR ) was one of the top performers in the biotechnology sector last year, gaining more than 180%. The gains were driven by investor enthusiasm for Aegerion's only approved drug, Juxtapid (lomitapide), a treatment for homozygous familial ...
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.